Page 2 - Devin Mclaughlin News Today

CHICAGO — Adjuvant osimertinib conferred a significant OS benefit vs. placebo among patients with resected, EGFR-mutant, stage IB to IIIA non-small cell lung cancer, according to results of the ADUARA trial presented at ASCO Annual Meeting.The findings, set to be published in The New England Journal of Medicine, provided further evidence that the addition of osimertinib (Tagrisso,

CHICAGO — Vorasidenib significantly improved PFS while delaying time to next intervention among certain patients with grade 2 isocitrate dehydrogenase 1- or 2-mutant glioma, according to data presented at ASCO Annual Meeting.The findings, published simultaneously in The New England Journal of Medicine, showed efficacy across all patient subgroups.

CHICAGO — The addition of nivolumab vs. brentuximab vedotin to AVD chemotherapy significantly reduced the risk for disease progression and disease-related death among adults with previously untreated advanced classic Hodgkin lymphoma.Results of the randomized phase 3 SWOG S1826 trial, presented at ASCO Annual Meeting, showed a 52% improvement in PFS with the nivolumab (Opdivo, Bristol Myers

CHICAGO — Administering modified FOLFIRINOX chemotherapy before chemoradiation, surgery and adjuvant chemotherapy improved survival outcomes of patients with locally advanced rectal cancer, according to results of the PRODIGE 23 trial.“The most important point of PRODIGE 23 is the overall survival benefit,” Thierry Conroy, MD, of the department of medical oncology at Institut de

CHICAGO — Adding talazoparib to atezolizumab as maintenance treatment after front-line chemoimmunotherapy significantly lengthened PFS among adults with SLFN11-positive extensive-stage small cell lung cancer, according to a phase 2 study.Results of the randomized trial presented at ASCO Annual Meeting suggested that a biomarker-based approach to treating small cell lung cancer is feasible

CHICAGO — Neoadjuvant FOLFIRINOX chemotherapy failed to extend OS compared with upfront surgery for patients with resectable pancreatic head cancer, according to study results presented at ASCO Annual Meeting.“Neoadjuvant FOLFIRINOX showed acceptable safety and resectability rates,” Knut Jørgen Labori, MD, PhD, of the department of hepato-pancreato-biliary surgery at Oslo

CHICAGO — First-line chemotherapy plus bevacizumab and durvalumab — followed by maintenance durvalumab, bevacizumab and olaparib — extended PFS compared with standard of care for women with non-BRCA-mutated advanced ovarian cancer.The findings of an interim analysis of the three-arm, randomized phase 3 DUO-O trial, presented at ASCO Annual Meeting, also noted a numerical

Norman Merrill II, 46, pleaded guilty in December to one count of possession of child sexual abuse materials, according to court documents. Two remaining counts were dismissed.

The FDA expanded the approval of abemaciclib, combined with endocrine therapy, as adjuvant treatment for adults with hormone receptor-positive, HER2-negative, node-positive early breast cancer. The label expansion removes the Ki-67 score requirement for selection of patients for treatment with abemaciclib (Verzenio, Eli Lilly), a cyclin-dependent kinase (CDK) 4/6 inhibitor. Patients with

Are you interested in exploring abstract painting?